February 23, 2026

FDA Approves New Option in Obesity

The Allurion Gastric Balloon System is now authorized by the US Food and Drug Administration for short-term weight loss in adults aged 22 to 65 years with obesity and a body mass index of 30 to 40 kg/m2.

Conexiant

February 18, 2026

Combo Therapy for Psoriasis With Obesity

A phase 3b trial tests ixekizumab plus tirzepatide in adults with moderate-to-severe plaque psoriasis and obesity or overweight.

Conexiant

February 12, 2026

FDA Approves Device for Pancreas Care

In the phase 3 PANOVA-3 trial, adding Tumor Treating Fields therapy to gemcitabine and nab-paclitaxel was associated with improved overall survival and delayed pain progression in adults with locally advanced pancreatic cancer.

Conexiant

February 11, 2026

AMA Backs Structured Vaccine Review

Medical societies and public health groups will collaborate on policy questions and evidence briefs for the 2026 to 2027 respiratory virus season.

Conexiant

January 27, 2026

The Exam Room Is Listening Now

As AI quietly enters exam rooms, physicians report real relief—and real concerns about accuracy, trust, and control.

KFF Health News

January 13, 2026

FDA Drops Warning From GLP-1 RAs

The FDA asked manufacturers to remove suicidal ideation and behavior warnings from select GLP-1 RAs after a comprehensive safety evaluation.

Conexiant

January 13, 2026

FDA Drops Warning From GLP-1 RAs

The FDA asked manufacturers to remove suicidal ideation and behavior warnings from select GLP-1 RAs after a comprehensive safety evaluation.

Conexiant

January 07, 2026

Protein-First Policy Hits US Tables 

New 2025 to 2030 Dietary Guidelines for Americans shift focus to whole foods, full-fat dairy, and protein prioritization while targeting ultraprocessed products as chronic disease drivers

Conexiant

January 07, 2026

Routine vs. Risk-Based Vaccination

The CDC has dropped routine recommendations for six childhood vaccines, shifting decisions to parents and doctors despite decades of evidence showing the shots prevented millions of hospitalizations and tens of thousands of deaths.

KFF Health News

January 02, 2026

NK-1 Drug Fills Motion Sickness Gap

Tradipitant demonstrates 50% to 70% risk reduction for vomiting incidence during motion exposure in phase 3 trials.

Conexiant